Dinoprost

Intra-amniotic
Pregnancy termination in the 2nd trimester

Pelvic infection; history of pelvic inflammatory disease. Active cardiac, pulmonary, renal or hepatic disease. Smoker.

Glaucoma or raised intraocular pressure, asthma or a history of asthma, epilepsy or a history of epilepsy, hepatic or renal dysfunction, CV disease. Do not administer by the myometrial route. Do not administer by the extraamniotic route in patients with cervicitis or vaginal infections. Monitor uterine activity, foetal status, cervical dilatation progress. In the induction of labor, carefully evaluate cephalopelvic relationships before use. Possibility of uterine rupture. Caution in patients with membrane rupture.

Bronchoconstriction; nausea; vomiting; diarrhoea; abdominal pain; flushing; shivering; headache; dizziness; hypotension; sudden CV collapse; hypertension; hypersensitivity reactions; convulsions; EEG changes; local tissue irritation; erythema; pyrexia; raised white cell count; local infection; excessive uterine activity; uterine rupture; cervical laceration and rupture; foetal distress and rarely fetal death.

Potentiates uteronic effect of oxytocin.

Description:
Mechanism of Action: Dinoprost is a prostaglandin with actions on smooth muscles. It induces contraction of uterine muscles and acts predominantly as a vasoconstrictor on blood vessels and a bronchoconstrictor on bronchial muscles.

Drugs Acting on the Uterus